People Science, a direct-to-consumer scientific research company providing a scaled research and development (R&D) platform for alternative medicines, today announced $5.3 million in a second seed round of funding led by Acre Venture Partners with participation from Bluestein Ventures, THIA Ventures and FORM Life Ventures. This brings their total seed funding to $8.5M with the prior seed round supported by Noetic Fund, Woven Science, and LifeForce Capital. The company will use the new capital to support their expansion into nutrition and food as medicine alongside their existing research efforts on natural and synthetic psychedelics, the microbiome, cannabis and cannabinoid medicines and digital health interventions. Lucas Mann, Co-Founder and Managing Partner at Acre Venture Partners, will join the People Science Board of Directors.

People Science is building a people-forward clinical research infrastructure to support the evolution, knowledge and understanding of alternative medicines. As a technology-enabled clinical research services company, People Science empowers individuals to answer the question, 'Which alternative medicines work best for me?' through their proprietary CHLOE app. People Science connects clients who make or want to promote the understanding of alternative medicines to the people who test their products.